Skip to main content
. 2021 Aug 24;41(11):1941–1947. doi: 10.1007/s00296-021-04975-4

Table 1.

Dilemmas in treating patients with ANCA vasculitis during the COVID-19 pandemic

1. Choice of induction and maintenance agent (since rituximab associates with higher risk of COVID)
2. Use of corticosteroids for induction in a patient with concomitant ANCA vasculitis flare and COVID-19
3. Testing for COVID-19 routinely in patients with vasculitic flares in the absence of clinical symptoms for COVID-19